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Abstract
On April 21, 2015, the first SCN8A Encephalopathy Research Group convened in Washington, 
DC, to assess current research into clinical and pathogenic features of the disorder and prepare an 
agenda for future research collaborations. The group comprised clinical and basic scientists and 
representatives of patient advocacy groups. SCN8A encephalopathy is a rare disorder caused by de 
novo missense mutations of the sodium channel gene SCN8A, which encodes the neuronal sodium 
channel Nav1.6. Since the initial description in 2012, approximately 140 affected individuals have 
been reported in publications or by SCN8A family groups. As a result, an understanding of the 
severe impact of SCN8A mutations is beginning to emerge. Defining a genetic epilepsy syndrome 
goes beyond identification of molecular etiology. Topics discussed at this meeting included (1) 
comparison between mutations of SCN8A and the SCN1A mutations in Dravet syndrome, (2) 
biophysical properties of the Nav1.6 channel, (3) electrophysiologic effects of patient mutations on 
channel properties, (4) cell and animal models of SCN8A encephalopathy, (5) drug screening 
strategies, (6) the phenotypic spectrum of SCN8A encephalopathy, and (7) efforts to develop a 
bioregistry. A panel discussion of gaps in bioregistry, biobanking, and clinical outcomes data was 
followed by a planning session for improved integration of clinical and basic science research. 
Although SCN8A encephalopathy was identified only recently, there has been rapid progress in 
functional analysis and phenotypic classification. The focus is now shifting from identification of 
the underlying molecular cause to the development of strategies for drug screening and prioritized 
patient care.
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Epilepsy is a common pediatric neurologic disorder, affecting up to 12 patients per 1,000.1 
Pharmacoresistant epilepsies make up 30% of cases and include epileptic encephalopathies 
(EEs). These severe disorders present in infancy or childhood and are characterized by 
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multiple seizure types and significant developmental slowing and regression.2 The frequent 
epileptic activity in EE is thought to contribute to cognitive and behavioral impairment. 
SCN8A encephalopathy is a newly defined EE caused by de novo mutations of the gene 
SCN8A encoding the sodium channel Nav1.6 (OMIM #614558). Most cases result from de 
novo mutations,3 with the exception of two cases of inheritance from a mosaic parent.4,5 The 
disorder typically presents with developmental epileptic encephalopathy within the first 2 
years of life.
SCN8A is one of nine human genes encoding voltage-gated sodium channel α subunits. 
Mutations of the related genes SCN1A and SCN2A are responsible for the EEs Dravet 
syndrome (OMIM #606208) and SCN2A encephalopathy (OMIM #613721). SCN1A, 
SCN2A, and SCN3A are also implicated in a range of milder, self-limited neonatal and 
infantile epilepsy syndromes.6–11 Targeted and genome-wide next-generation sequencing 
has greatly increased the number of individuals identified with SCN8A encephalopathy, 
allowing researchers to prioritize functional studies and develop an understanding of the 
phenotypic spectrum.12–14
Mutations of SCN1A in patients with inherited epilepsy and the sporadic Dravet syndrome 
were first identified in 2000 and 2001.11,15 Since then, a substantial body of knowledge 
regarding prognosis, comorbidities, optimal care, and quality of life has become available. In 
contrast, SCN8A encephalopathy was first identified in 2012, and an understanding of the 
severe impact of SCN8A mutations is just beginning to emerge.16 Awareness of this need, 
fueled by devoted, caring, and highly informed families, led to the first SCN8A research and 
family advocacy group meeting in Washington, DC, on April 21, 2015. The goal of the 
meeting was to review current knowledge and identify future needs for patient care groups 
and clinical investigators. Herein we discuss these efforts and future steps for the SCN8A 
community in advancing toward therapeutic trials and improved outcomes.
Clinical Aspects: Phenotype of SCN8A Encephalopathy
The frequency of SCN8A mutations in patients with EE was measured in four recent studies 
that in combination identified 13 cases in 1,157 EE patients.4,13,17,18 SCN8A mutations thus 
appear to account for approximately 1% of EE. More than 140 individuals with EE are 
known to have SCN8A mutations, including 50 published and 90 unpublished cases 
(SCN8A Family Group, personal communication, April 2015).12,13,16,18–22 The location 
within the Nav1.6 channel protein of 31 published SCN8A mutations from 50 patients is 
shown in Figure 1. The number is rapidly growing with the inclusion of SCN8A in clinical 
epilepsy gene panels and the expanded use of whole exome sequencing for diagnostic 
evaluation of patients with epilepsy syndromes.3,13,29
Within SCN8A encephalopathy, individuals have been diagnosed with syndromes including 
unclassified EE, early infantile EE, and Dravet-like presentation.12,13,16,18–22 The mean age 
of seizure onset for SCN8A encephalopathy is 4–5 months, with a range from the first day 
of life to 18 months, and in utero seizures may be part of the clinical spectrum.12,16,19,24–26 
Tonic–clonic seizures are often seen at onset, and these are usually not triggered by fever (25 
individuals reported).12,13,16,18–22 Most of the 50 patients in published series have multiple 
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seizures types including tonic (21 individuals), absence seizures (10 individuals), myoclonic 
(10 individuals), focal (6 individuals), clonic (6 individuals), and epileptic spasms (6 
individuals).12,13,16,18–22 In addition, 11 of the 50 individuals were reported to have 
convulsive or nonconvulsive status epilepticus.12,13,16,18–22 Electroencephalography (EEG) 
features include diffuse moderate to severe background slowing with focal or multifocal 
epileptiform abnormalities.13 Magnetic resonance imaging (MRI) brain studies are typically 
normal with a few reports of progressive cerebral atrophy.13
The majority of affected individuals have pharmacoresistant seizures and a mixed response 
to antiepileptic drugs (AEDs).13 Several individuals have had a positive response to sodium 
channel blocking drugs such as valproic acid, phenytoin, carbamazepine, and 
oxcarbazepine.13,20,30 Families have reported both positive and negative responses to some 
of the more widely used AEDs.
Although development of an infant with SCN8A encephalopathy may be delayed from birth, 
in many cases development is normal prior to seizure onset. After seizure onset, among 50 
published cases,12,13,16,18–22 development slowed in 29 individuals and regressed in 10 
individuals. Intellectual disability was common, and ranged from mild (n = 2) to moderate (n 
= 15) or severe (n = 23). Motor features included hypotonia (n = 22), ataxia (n = 13), 
dystonia (n = 6), hyperreflexia (n = 4), and choreoathetosis (n = 4).12,13,16,18–22 Eleven 
individuals had no speech. In some cases, immobility leading to wheelchair dependence 
developed during disease progression (n = 10). Sudden unexpected death in epilepsy 
(SUDEP) was reported in five individuals. Most of the published patients are in the first two 
decades of life.
Comparison of SCN8A Encephalopathy with Dravet Syndrome (SCN1A) and 
SCN2A Encephalopathy
Three recognized sodium channel gene EEs are caused by mutations in SCN8A, SCN1A 
(Dravet syndrome), SCN2A, and SCN8A.11,16,31 The mean age at onset is similar in 
SCN8A encephalopathy and Dravet syndrome, but the variation is broader in SCN8A 
encephalopathy (neonatal period to 18 months of age) compared with Dravet syndrome 
(neonatal period to 12 months of age). Onset during the first week of life is frequently 
observed for SCN2A encephalopathy.31
Although febrile seizures are the hallmark at presentation in the majority of infants with 
SCN1A mutations, they are rare in SCN8A and SCN2A encephalopathies. Epileptic spasms 
are not a feature of Dravet syndrome but can occur in SCN8A and SCN2A 
encephalopathies. There is an important difference in response to treatment with sodium 
channel blockers. Patients with Dravet syndrome are well known to respond adversely to 
carbamazepine and phenytoin, for example, whereas these and other sodium channel 
blockers may be efficacious in SCN8A and SCN2A encephalopathies. EEG recordings in 
Dravet syndrome exhibit generalized spike wave activity as well as multifocal discharges.7 
In contrast, SCN8A and SCN2A encephalopathies have predominantly focal and multifocal 
epileptiform discharges and voltage attenuation during epileptic spasms.31
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All three sodium channel EEs are associated with a high mortality rate of approximately 10–
15% by age 20, based on published reports. The rate of SUDEP in the sodium channel 
encephalopathies seems to be higher than in other disorders such as PCDH19 
encephalopathy.7,31
As discussed below, most SCN8A mutations in EE are missense mutations that cause 
increased Nav1.6 channel activity. The same is true for SCN2A mutations in EE. In contrast, 
most SCN1A mutations in Dravet syndrome result in reduced Nav1.1 activity. This 
fundamental difference in mechanism is likely to explain why sodium channel blockers can 
be effective for some patients with SCN8A encephalopathy, who have an excess of SCN8A 
channel activity, but may exacerbate seizures in Dravet syndrome patients with a deficiency 
of SCN1A channel activity. This difference in drug response is one important reason to 
prioritize early genetic testing, since the results directly influence patient management.
Characteristics of Sodium Channel Nav1.6 Encoded by SCN8A
SCN8A encodes the sodium channel α subunit Nav1.6, the current-conducting component of 
a complex that also contains modulatory β subunits.32 As a member of the voltage-gated 
sodium (Nav) channel family, Nav1.6 has the typical structure with four homologous 
domains (DI–DIV), each containing six transmembrane segments (S1–S6) (Fig. 1). Voltage 
sensitivity is provided by positively charged arginine and histidine residues in the four S4 
transmembrane segments. The channel “fast-inactivates” through a hingedlid mechanism 
(internal DIII–DIV linker) that occludes the intracellular mouth of the pore (composed of the 
S5–S6 segments of all four domains). A second, less well-defined “slow” inactivation 
mechanism may involve a collapse of the outer mouth of the pore.33 The unique properties 
of Nav1.6 were reviewed recently.29 Nav1.6 is predominantly expressed in neurons, and is 
one of the most abundant sodium channels in the central nervous system (CNS). Nav1.6 is 
also expressed at a low level in heart.34–36 SCN8A transcripts are readily detected in 
prenatal brain. Adult levels of expression and splicing are reached by 1 month in the 
mouse,37,38 and between 1 and 9 years of age in humans.39 Expression of Nav1.6 is 
widespread throughout the central and peripheral nervous system in both excitatory and 
inhibitory neurons.29,37 An important aspect of Nav1.6 biology is its concentration at two 
specialized membrane domains: the axon initial segment (the site of action potential 
initiation) and the node of Ranvier (the site of action potential regeneration during axonal 
saltatory conduction).40–46 These localizations of Nav1.6, and its variable expression in 
different types of neurons, contribute to the unique features of SCN8A channelopathies.
Many biophysical properties of Nav1.6 resemble the other neuronal Nav channels, including 
voltage dependence and kinetics of inactivation and recovery.29 However, Nav1.6 uniquely 
generates higher levels of persistent and resurgent current, both of which contribute to 
repetitive neuronal firing.47,48 A working hypothesis for the mechanism of increased seizure 
susceptibility resulting from SCN8A gain-of-function mutations is that mutant Nav1.6 
mediates elevated transient, persistent, and/or resurgent sodium current. This hypothesis is 
supported by the functional analysis described in a later section, which has demonstrated 
that many disease-linked mutations directly increase channel activity. This hypothesis is 
consistent with studies in the mouse indicating that reduced Scn8a activity reduces seizure 
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susceptibility.49 One approach to developing new treatments for SCN8A epilepsies is 
therefore to identify drugs that specifically block Nav1.6. The extensive conservation 
between Nav1.6 and the other Nav channels has made this challenging.
Alternative Splicing and Rare Introns of SCN8A
The SCN8A gene contains two pairs of alternatively spliced exons that encode 
transmembrane segments S3 and S4 of domain I and domain III.38 Both of these mutually 
exclusive exon pairs contain one neonatal (N) and one adult (A) exon. In domain I, the 
alternative exons differ by a single amino acid. In domain III, the neonatal exon contains an 
in-frame stop codon that results in protein truncation. Expression of the adult exon with the 
open-reading frame is restricted to neurons38,39 and a low level in heart,35 whereas 
transcripts containing the in-frame stop codon are widely expressed at a low level in 
nonneuronal tissues. Another unusual feature of the SCN8A gene is the presence of two 
minor-class introns whose splice sites begin with an AT dinucleotide and end with AC, 
rather than the major-class GT and AG.50 These nonconsensus splice sites influence the 
pattern of exon skipping that results from mutations in nearby splice sites.50
Patient Mutations in SCN8A Encephalopathy
Patient mutations of SCN8A arise de novo in the affected individual and result in a single 
amino acid substitution rather than protein truncation. In contrast, the mutations of SCN1A 
in Dravet syndrome also arise de novo, but 60% of mutations cause protein truncation and 
loss of function. Without functional studies, the effects of amino acid substitutions are not 
obvious. Software algorithms such as PhyloP,51 SIFT,52 and PolyPhen-253 provide estimates 
of pathogenicity based on evolutionary conservation of the substituted amino acid and the 
chemical difference between the original amino acid and its replacement. Nonetheless, 
reliable predictions regarding the biophysical consequences of amino acid substitutions are 
not yet possible. Functional comparisons between wild-type and mutant Nav channels can be 
made experimentally, using electrophysiologic patch-clamp experiments, but require 
extensive laboratory investigation. Ten missense mutations of SCN8A have thus far been 
functionally evaluated for their effect on Nav1.6 channel activity,3,12,16,22,29,54 and eight 
(80%) resulted in elevated channel activity. Because sodium channels are involved in 
initiation and propagation of action potentials, elevated sodium channel activity in excitatory 
neurons can lead to central hyperactivity, the hallmark of seizures. Three functional changes 
leading to elevated channel activity in the mutated channels are illustrated in Figure 2: 
premature channel opening, impaired channel closing, and increased persistent 
current.3,12,16,22,29,54 These are classified as “gain-of-function” effects because they produce 
new channel properties not seen in the wild-type channel. (This is in distinction to “loss of 
function” mutations that reduce activity, often by protein truncation, as in Dravet syndrome.)
With the relatively small number of mutations analyzed to date, no clear correlation between 
phenotypic severity and genetic mutation has emerged. Patients with the identical genetic 
variant can differ in clinical severity, demonstrating an important role of genetic background, 
and possibly environment, in clinical outcome. For example, the mutation p.Arg1617Gln has 
been identified in five unrelated patients. This mutation replaces a positively charged 
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arginine residue with an uncharged glutamine residue in transmembrane segment 4 of 
domain IV. Functional analysis demonstrated impaired inactivation,54 as predicted by the 
loss of a gating charge in the S4 segment of the domain IV voltage sensor, a region known to 
influence fast inactivation.3,55 The age of seizure onset among the five patients with this 
mutation varied from 3 to 12 months, the ability to sit without assistance was achieved 
between 8 and 24 months of age, and the EEG patterns and responses to medication were 
heterogeneous.3 This type of phenotypic heterogeneity is observed in other genetic 
epilepsies, for example among mutations of the potassium channel KCNT1.56
The SCN8A gene contains several hot spots for recurrent mutations (indicated in Fig. 1). 
The 50 published cases include 19 recurrent mutations each identified in two to five 
unrelated individuals. Analysis of patients with recurrent mutations may permit 
identification of the contribution of genetic background and identification of modifier genes.
Mutations of SCN8A Can Cause Other Less Severe Disorders
One inherited SCN8A mutation with loss of channel function due to protein truncation 
resulted in moderate intellectual disability without seizures in four related heterozygous 
carriers.57 The proband in this family had ataxic gait and cerebellar hypoplasia. Another 
mosaic, de novo intragenic deletion of SCN8A spanning exons 2–14 was identified in an 
individual with intellectual disability and absence seizures, but no convulsive seizures. The 
inherited SCN8A variant p.Glu1483Lys was described in three unrelated families with 
benign infantile seizures, paroxysmal dyskinesis, and normal cognition.58 Thus, missense 
mutations of SCN8A can result in less severe disorders than EE.
Distinguishing between pathogenic and nonpathogenic missense variants is a major 
challenge in interpretation of genetic test results for SCN8A. Although most de novo patient 
mutations are likely to be pathogenic, it is not always the case. For example, the de novo 
missense mutation p.Asp58Asn in the cytoplasmic N terminus of SCN8A did not alter 
function and may be a nonpathogenic bystander.19 Several patients have de novo variants 
that are present in exome databases at low frequencies and may be nonpathogenic. Other 
missense mutations affect amino acid residues that are not well conserved during evolution, 
suggesting that they may be nondeleterious. Thus, identification of a de novo SCN8A 
variant in a patient should be followed up with expert interpretation.
iPSC-Derived Neuron Models of SCN1A and SCN8A Epilepsies
An efficient platform for development of precision therapy based on the electrophysiologic 
impact of individual mutations may come from induced pluripotent stem cells (iPSCs), 
reprogrammed from patient-derived skin or blood cells. The generation of neurons from 
iPSCs has been used in Dravet syndrome to characterize sodium current density using 
whole-cell voltage- and current-clamp recordings.59–61 The use of iPSCs provides a robust 
modeling tool, permitting the physiologic properties of multiple cell types with identical 
genotype to be examined. Study of different mutations may yield insight into the influence 
of a single mutation in different cell types.3,54,60 In iPSCs, the mutant channels are 
expressed in cells with the precise genetic background of the patient, which affords 
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functional analyses of unparalleled physiologic accuracy. CRISPR/Cas gene editing can be 
used to generate isogenic control lines with the mutation corrected for comparison. The 
technique is not without challenges, however, and independent studies have produced 
different outcomes.59–61 Nonetheless, iPSC disease models constitute, at present, the most 
native and flexible drug-testing platform. iPSCs can also be differentiated into cardiac 
myocytes, permitting analysis of pathogenic mechanisms that may contribute to SUDEP in 
SCN8A encephalopathy.
Strategies to Screen for Effective Therapies for SCN8A Encephalopathy
Existing SCN8A cell and mouse models provide an opportunity for early screening in vitro 
to be followed by in vivo testing based on appropriate evidence. Generation of SCN8A 
mutations in zebrafish may provide another model applicable to drug screening, as for 
SCN1A to model Dravet syndrome.62,63 The National Institutes of Health (NIH) 
Anticonvulsant Drug Development Program at the University of Utah provides a low-
throughput but rigorous testing program to narrow down drug selection, accounting for 
efficacy as well as toxicity and safety issues.64 All AEDs that have advanced to clinical trials 
have passed through this program since its inception in 1975. Surveying libraries of U.S. 
Food and Drug Administration (FDA)–approved compounds may provide an expedited 
opportunity for effective and approved therapies for SCN8A diseases.
Modeling SCN8A Mutations in the Mouse
Mouse models are useful for understanding pathogenic mechanisms as well as evaluation of 
new treatments emerging from cell-based screening programs. A mouse model carrying the 
first published patient mutation of SCN8A (p.Asn1768Asp) has been described.65 These 
mice recapitulate the seizures, EEG abnormalities, and premature death that were observed 
in the original patient (Fig. 3).14,16 This mutation causes impaired channel inactivation, 
increased persistent current, and elevated channel activity.16 In addition to hyperexcitable 
neurons, the Scn8a mutant mice display abnormal firing of ventricular myocytes, suggesting 
that cardiac arrhythmia may contribute to SUDEP in SCN8A encephalopathy (CR Frasier 
and LL Isom, unpublished data). These mice and additional lines with other patient 
mutations will be important for preclinical testing of current and novel therapies. Correlating 
biophysical abnormalities of SCN8A mutants with in vivo responses may eventually provide 
personalized recommendations for treatment of newly diagnosed patients. Many 
fundamental questions can be addressed with mouse models, such as the impact of gain-of-
function SCN8A mutations on various classes of neurons and on inhibitory versus general 
circuits.
Gaps in Bioregistry, Biobanking, and Clinical Outcome Information that 
Must Be Filled to Become Trial Ready
Building on the emerging molecular understanding of SCN8A encephalopathy, there is 
urgent need to develop clinical platforms for testing the efficacy of interventions. To be “trial 
ready” for assessing therapies for SCN8A encephalopathy, more data on the natural history 
of the disorder are needed, including a better understanding of the phenotypic spectrum. A 
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registry of mutations and the associated clinical outcomes will be essential. Comprehensive 
clinical data will be needed, including data regarding seizure phenotypes, developmental 
delay, developmental regression, movement disorders, other comorbidities, age at onset of 
later features, hospitalization rate, efficacy of antiepileptic and other medications, and 
survival. In combination with genomic studies, such a comprehensive database would also 
facilitate the systematic identification of modifier genes and pharmacogenetic interactions. 
Three important areas for development were discussed at the April 2015 meeting: 
bioregistry, biobanking, and documentation of clinical outcomes.
Bioregistry
Creation of a centralized registry would facilitate the early stages of research into innovative 
care for SCN8A-related disorders, and it will be important to identify long-term support for 
database maintenance and moderation. A community website hosting a patient-reported 
registry, modeled on the Patient-centered Outcomes Research Institute-funded Rare Epilepsy 
Network developed for other genetic encephalopathies,66 is under development at the 
University of Arizona (www.SCN8A.net). This website provides information tailored to the 
interests of three groups: families, health care providers, and researchers. Features include 
the ability to determine whether an SCN8A variant has been previously reported, a directory 
of physicians who have treated patients with SCN8A mutations, and a private forum for 
families to ask questions and interact. The website includes information about scientific 
advances in SCN8A research, clinical tools developed for other early onset epileptic 
encephalopathies,67 and links to groups such as CURE (http://www.cureepilepsy.org). A 
feature under development is a patient-reported registry that will allow participants to 
provide consent online and to fill out an extensive questionnaire designed specifically for 
SCN8A-related disorders. New information on clinical features that are shared among 
children with SCN8A mutations has already emerged. Eventually, the data will include a 
complete curated list of all known SCN8A variants, pathogenic or of unknown 
pathogenicity, with cross-reference to clinical information from individuals carrying those 
mutations. These data will benefit the physicians treating patients whose molecular test 
detects a potentially pathogenic SCN8A alteration.
Development of a patient registry will also be key to the systematic evaluation of responses 
of SCN8A encephalopathy patients to standard AEDs. To go beyond anecdotal reports, it 
will be necessary to combine detailed information for a cohort of patients, including clinical 
status prior to treatment, with precise data on dosage, timing of drug administration, and 
clinical impact. The frequent use of poly therapy, or combinations of AEDs, remains a 
confounding feature in sorting out the efficacy of specific AEDs. Lessons may be learned 
from a recent effort to assess AED effectiveness in a cohort of 58 patients with PCDH19 
mutations based on retrospective reports of caregivers.68 With the expansion of early genetic 
testing, it may become possible in the future to carry out prospective studies of sequential 
monotherapy that could provide more definitive data.
The benefits of crowd-sourcing for this rare disorder are becoming clear, with the number of 
patient-reported mutations (n = 140) now exceeding those in the published literature (n = 
50). However, a disadvantage of patient-reported registries is the lack of data from medical 
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records. It may become possible for patients/caregivers to request their records and upload 
them to a website or send them to the registry. In studies of very rare conditions, highly 
motivated participants may enroll in multiple studies or registries being conducted by 
different investigators. Results from these studies may appear to be confirmatory when in 
fact they are derived from overlapping patient populations.
Biobanking
Biobanking of patient samples with standardized sample collection is another high priority 
for advancing understanding and therapy for SCN8A encephalopathy. In combination with 
an online registry, collection of high-quality specimens with confirmed SCN8A mutations 
will facilitate the development of genotype/phenotype correlations. Modeling with patient-
derived cells, by reprogramming of skin cells and peripheral blood monocytes, has already 
provided insight into the pathogenic roles of Nav1.6. In the circumstance of SUDEP, 
mechanisms will be better investigated by banking tissue, fibroblast cultures, and DNA. As 
with all biobanking, quality control and making specimens available to the research 
community will be critical.
Clinical outcomes
Effective recording of clinical outcomes will require better definitions and methods of 
assessment. To advance the quality of patient self-reporting in clinical research and practice, 
the NIH has developed PROMIS, the Patient-Reported Outcomes Measurement Information 
System. This initiative is developing new ways to measure patient-reported outcomes 
(PROs) that impact quality-of-life such as pain, fatigue, physical functioning, emotional 
distress, and social role participation. Work is needed to develop additional PROs specific to 
epilepsy. In one such study, Berg and collaborators investigated the outcomes most highly 
valued by parents of children with epilepsy and found that highest priority was given to 
seizure freedom and improved cognition.69,70 Epilepsy patient support groups are also 
developing approaches to monitoring outcomes.
Conclusions
Previous experience with Dravet syndrome has demonstrated that understanding a genetic 
epilepsy syndrome requires more than identification of the molecular etiology. Careful 
clinical and electrophysiologic phenotyping will be required to reveal the consequences of 
specific SCN8A mutations and to personalize AED choice for patients. In parallel with 
continuing research on disease mechanisms, the development of robust natural history and 
outcome measures will be essential to evaluating targeted therapeutics. These data will 
ultimately reveal whether developmental outcomes can be affected by early intervention and 
informed choice of AED. With the availability of a mouse model of SCN8A encephalopathy 
and additional models in development, there should be a concerted effort to test the 
clinically available drugs to identify the agents most likely to be successful in clinical trials. 
Mouse models can also address fundamental questions such as the impact of a gain-of-
function mutation of Nav1.6 on inhibitory neuronal circuits.
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Further efforts will be enhanced by the development of an interface between patients, 
clinicians, and researchers. Biobanking, and partnership with established epilepsy and 
SCN8A advocacy groups will be important steps. Although SCN8A encephalopathy was 
only recently discovered, important findings from functional studies and phenotypic 
classification has already shifted the focus from mutation identification to functional 
analysis and drug screening. These important steps have implications for all parties invested 
in SCN8A encephalopathy, as we work toward reducing the uncertainty that comes with this 
diagnosis, often obtained after a prolonged diagnostic odyssey.
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Key Points
• SCN8A encephalopathy was first identified in 2012, and an understanding of 
the severe impact of SCN8A mutations is emerging
• SCN8A mutations account for approximately 1% of epileptic 
encephalopathies overall, >140 individuals have been identified to date
• Distinctive properties of the sodium channel Nav1.6 include a higher level of 
persistent and resurgent currents and localization at the axon initial segment 
(AIS) and nodes of Ranvier
• Distinguishing between pathogenic and nonpathogenic variants is a challenge 
for interpretation of missense mutations of SCN8A
• Rapid progress in functional studies and phenotypic classification has focused 
current attention on the development of strategies for drug screening and 
assessment
Meisler et al. Page 15
Epilepsia. Author manuscript; available in PMC 2017 July 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Locations of missense mutations in SCN8A encephalopathy. The Nav1.6 channel encoded 
by SCN8A is composed of four homologous domains (DI to DIV), each containing six 
transmembrane segments (S1–S6). The channel also contains intracellular N-terminal and C-
terminal domains, two large intracellular loops, and a small intracellular loop between 
domain III and domain IV, which functions as the inactivation gate. Thirty-one published de 
novo mutations that were identified in 50 unrelated patients are shown. Pathogenic 
mutations are concentrated in transmembrane segments and in the N- and C-terminal 
domains. Black symbols, one patient; blue symbols, recurrent mutations found in multiple 
patients (Adapted from Wagnon and Meisler3). [Correction added after online publication on 
June 13, 2016: figure credit changed from Takahashi et al. to Wagnon and Meisler.]
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Figure 2. 
Effects of gain-of-function mutations in SCN8A in patients with epileptic encephalopathy. 
(A) The Thr767Ile substitution in transmembrane segment S1 of domain II causes a 
hyperpolarizing shift in the voltage dependence of activation, resulting in premature channel 
opening.22 (B). Three mutations of Arg1872 in the cytoplasmic C-terminal domain remove a 
critical positive charge resulting in delayed channel inactivation.54 (C) The substitution 
Asn1768Asp in transmembrane segment S6 of domain IV results in an increase in persistent 
sodium current that facilitates repetitive firing.16 [Correction added after online publication 
on June 13, 2016: reference numbers updated for parts (A), (B), and (C) in the caption.]
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Figure 3. 
A mouse model of SCN8A encephalopathy generated by knock-in of the patient mutation 
p.Asn1768Asp (N1768D). Approximately 45% of the heterozygous D/+ mice develop 
abnormal EEG findings and seizures leading to premature death before 6 months of age. 
Homozygous D/D mice and hemizygous D/− mice are more severely affected. The number 
of mice in each group is shown in parentheses (adapted from Wagnon et al.14). [Correction 
added after online publication on June 13, 2016: figure credit changed from Takahashi et al. 
to Wagnon et al.]
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